Maxim Group Cuts Price Target on Galena Biopharma (GALE) After Meeting with Management
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Galena Biopharma to Host Webcast and Conference Call Today
July 8, 2016 7:35 AM EDTSAN RAMON, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the Company will host a conference call this morning to discuss todays financing, the interim analysis on the Phase 3 trial, and provide an update on the Companys clinical development programs.
The webcast and conference call will take place today at 9:00 a.m. P.T./12:00 p.m. E.T.
The webcast can be accessed on the Company's website under the... More
Galena Biopharma Announces Pricing of Registered Direct Offering
July 8, 2016 7:05 AM EDTSAN RAMON, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major medical needs, today announced that it has entered into securities purchase agreements with certain institutional investors providing for the issuance of 28,000,000 shares of common stock at a purchase price per share of $0.45 in a registered direct offering, and warrants to purchase up to 14,000,000 shares of common stock with an exercise price of $0.65 per share in a concurrent private placement, resulting in gross proceeds to the Company of... More
